TABLE 2.
Pfizer | Moderna | Janssen | Any COVID vaccine a | |
---|---|---|---|---|
COVID Vaccine Administration 1/1/2021 to 6/14/2021 | ||||
N doses of vaccine administered | 166,981,930 (54%) | 128,084,622 (42%) | 11,606,202 (4%) | 306,907,697 |
N patients who received at least 1 dose | 90,063,644 | 72,705,161 | 11,465,768 | 174,234,573 |
N patients who received full vaccine course | 75,374,466 | 58,015,983 | 11,465,768 | 144,919,339 |
VAERS Vaccine Side Effect Data 1/1/2021 to 6/14/2021 | ||||
N side effect entries (inclusive), % of vaccine doses administered | 126,901 (0.08%) | 148,674 (0.12%) | 38,194 (0.33%) | 314,610 (0.10%) |
N side effect entries (neuro), % of vaccine doses administered | 44,896 (0.03%) ^# | 42,368 (0.03%) ^! | 17,622 (0.15%) #! | 105,214 (0.03%) |
Age in VAERS‐yr, (median, IQR) | 49 (35–64)^# | 52 (37–66)^! | 44 (31–57)#! | 50 (35–64) |
Sex in VAERS (% F) | 71%^# | 74%^! | 62%#! | 71% |
# days from vaccine to symptom onset (median, IQR) | 1 (0–2)^# | 1 (0–6)^! | 0 (0–2)#! | 1 (0–3) |
N (%) symptoms reported after: | ||||
1st dose | 50%^ | 57%^ | – | 54% |
2nd dose | 35% | 28% | 28% | |
Missing | 15% | 15% | 18% |
Includes Pfizer, Moderna, Janssen and unspecified manufacturer (n = 841); ^p < 0.001 Pfizer v Moderna, #p < 0.001 Pfizer v Janssen, !p < 0.001 Moderna v Janssen.